000125509 001__ 125509
000125509 005__ 20240228143312.0
000125509 0247_ $$2doi$$a10.1159/000449412
000125509 0247_ $$2pmid$$apmid:27756074
000125509 0247_ $$2ISSN$$a0012-2823
000125509 0247_ $$2ISSN$$a0301-164X
000125509 0247_ $$2ISSN$$a0365-8228
000125509 0247_ $$2ISSN$$a0365-8325
000125509 0247_ $$2ISSN$$a1421-9867
000125509 037__ $$aDKFZ-2017-01635
000125509 041__ $$aeng
000125509 082__ $$a610
000125509 1001_ $$0P:(DE-He78)68cbca3e3973d332ccc4c6e31a76b10c$$aBetge, Johannes$$b0$$eFirst author$$udkfz
000125509 245__ $$aOutcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative.
000125509 260__ $$aBasel$$bKarger$$c2016
000125509 3367_ $$2DRIVER$$aarticle
000125509 3367_ $$2DataCite$$aOutput Types/Journal article
000125509 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1521807297_19902
000125509 3367_ $$2BibTeX$$aARTICLE
000125509 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000125509 3367_ $$00$$2EndNote$$aJournal Article
000125509 520__ $$aThis study is aimed at analyzing the survival rates and prognostic factors of stage IV colorectal cancer patients from 3 European cohorts undergoing combination chemotherapy with bevacizumab.Progression free-survival (PFS) and overall survival (OS) were analyzed in 172 patients using the Kaplan-Meier method and uni- and multivariable Cox proportional hazards regression models.The median PFS was 9.7 and the median OS 27.4 months. Patients treated at centers in Germany (n = 97), Ireland (n = 32), and The Netherlands (n = 43) showed a median PFS of 9.9, 9.2, and 9.7 months, OS of 34.0, 20.5, and 25.1 months, respectively. Patients >65 years had a significantly shorter PFS (9.5 vs. 9.8 months) but not OS (27.4 vs. 27.5 months) than younger patients. High tumor grade (G3/4) was associated with a shorter PFS, T4 classification with both shorter PFS and OS. Fluoropyrimidine (FP) chemotherapy backbones (doublets and single) had comparable outcomes, while patients not receiving FP backbones had a shorter PFS. In multivariable analysis, age and non-FP backbone were associated with inferior PFS, T4 classification and therapy line >2nd were significantly associated with poor PFS and OS.The observed survival rates confirm previous studies and demonstrate reproducible benefits of combination bevacizumab regimens. Classification T4, non-FP chemotherapy backbone, and age >65 were associated with inferior outcome.
000125509 536__ $$0G:(DE-HGF)POF3-312$$a312 - Functional and structural genomics (POF3-312)$$cPOF3-312$$fPOF III$$x0
000125509 588__ $$aDataset connected to CrossRef, PubMed,
000125509 650_7 $$2NLM Chemicals$$aAngiogenesis Inhibitors
000125509 650_7 $$2NLM Chemicals$$aPyrimidines
000125509 650_7 $$02S9ZZM9Q9V$$2NLM Chemicals$$aBevacizumab
000125509 650_7 $$0675-21-8$$2NLM Chemicals$$a5-fluoropyrimidine
000125509 7001_ $$aBarat, Ana$$b1
000125509 7001_ $$aMurphy, Verena$$b2
000125509 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b3$$udkfz
000125509 7001_ $$aVan Grieken, Nicole C$$b4
000125509 7001_ $$aBelle, Sebastian$$b5
000125509 7001_ $$0P:(DE-He78)4730a4e3dbc9057824efb4d2be729786$$aZhan, Tianzuo$$b6$$udkfz
000125509 7001_ $$aHärtel, Nicolai$$b7
000125509 7001_ $$aKripp, Melanie$$b8
000125509 7001_ $$aBacon, Orna$$b9
000125509 7001_ $$aCordes, Martijn$$b10
000125509 7001_ $$aKay, Elaine W$$b11
000125509 7001_ $$aVerheul, Henk M W$$b12
000125509 7001_ $$aNeerincx, Maarten$$b13
000125509 7001_ $$aHennessy, Bryan$$b14
000125509 7001_ $$aHofheinz, Ralf D$$b15
000125509 7001_ $$aGaiser, Timo$$b16
000125509 7001_ $$aYlstra, Bauke$$b17
000125509 7001_ $$aPrehn, Jochen H M$$b18
000125509 7001_ $$aLambrechts, Diether$$b19
000125509 7001_ $$aByrne, Annette T$$b20
000125509 7001_ $$aEbert, Matthias P$$b21
000125509 7001_ $$aSchulte, Nadine$$b22
000125509 773__ $$0PERI:(DE-600)1482218-0$$a10.1159/000449412$$gVol. 94, no. 3, p. 129 - 137$$n3$$p129 - 137$$tDigestion$$v94$$x1421-9867$$y2016
000125509 909CO $$ooai:inrepo02.dkfz.de:125509$$pVDB
000125509 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)68cbca3e3973d332ccc4c6e31a76b10c$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000125509 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000125509 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4730a4e3dbc9057824efb4d2be729786$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000125509 9131_ $$0G:(DE-HGF)POF3-312$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunctional and structural genomics$$x0
000125509 9141_ $$y2016
000125509 915__ $$0StatID:(DE-HGF)0400$$2StatID$$aAllianz-Lizenz / DFG
000125509 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000125509 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bDIGESTION : 2015
000125509 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000125509 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000125509 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000125509 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000125509 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000125509 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000125509 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000125509 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000125509 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000125509 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000125509 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000125509 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000125509 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000125509 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000125509 9201_ $$0I:(DE-He78)B110-20160331$$kB110$$lSignalwege und Funktionelle Genomik$$x1
000125509 980__ $$ajournal
000125509 980__ $$aVDB
000125509 980__ $$aI:(DE-He78)C060-20160331
000125509 980__ $$aI:(DE-He78)B110-20160331
000125509 980__ $$aUNRESTRICTED